The Effect of Dutasteride on the Peripheral and Transition Zones of the Prostate and the Value of the Transition Zone Index in Predicting Treatment Response

Journal of Urology

Volumn 177, Issue 4, 2007, Pages 1408-1413

  Marks, Leonard S ^a   Roehrborn, Claus G ^b   Wolford, Eric ^c   Wilson, Timothy H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

disease progression; dutasteride; prostate; prostatic hyperplasia

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URINE FLOW RATE; URINE RETENTION;

AGED; AZASTEROIDS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX;

EID: 33947241792     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.11.095     Document Type: Article

References (20)

1. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol 12 (1988) 619
2. McNeal J.E. Origin and evolution of benign prostatic enlargement. Invest Urol 15 (1978) 340
3. McNeal J.E. The zonal anatomy of the prostate. Prostate 2 (1981) 35
4. Terris M.K., Afzal N., and Kabalin J.N. Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score, urinary flow rate, and post-void residual volume. Urology 52 (1998) 462
5. Kaplan S.A., Te A.E., Pressler L.B., and Olsson C.A. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 154 (1995) 1764
6. Witjes W.P., Aarnink R.G., Ezz-el-Din K., Wijkstra H., Debruyne E.M., and de la Rosette J.J. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. Br J Urol 80 (1997) 84
7. Lepor H., Nieder A., Feser J., O'Connell C., and Dixon C. Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol 158 (1997) 85
8. Tempany C.M., Partin A.W., Zerhouni E.A., Zinreich S.J., and Walsh P.C. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate 22 (1993) 39
9. Tewari A., Shinohara K., and Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 45 (1995) 258
10. Marks L.S., Partin A.W., Gormley G.J., Dorey F.J., Shery E.D., Garris J.B., et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 157 (1997) 2171
11. Marks L.S., Partin A.W., Dorey F.J., Gormley G.J., Epstein J.I., Garris J.B., et al. Long-term effects of finasteride on prostate tissue composition. Urology 53 (1999) 574
12. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
13. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172 (2004) 1314
14. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
15. Roehrborn C.G., Lukkarinen O., Mark S., Siami P., Ramsdell J., and Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 96 (2005) 572
16. Greene D.R., Egawa S., Hellerstein D.K., and Scardino P.T. Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology 36 (1990) 293
17. Marks L.S., Dorey F.J., Rhodes T., Shery E.D., Rittenhouse H., Partin A.W., et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol 156 (1996) 1035
18. Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., et al., PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 54 (1999) 662
19. Ives E.P., Gomella L.G., and Halpern E.J. Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results. Radiology 237 (2005) 197
20. Kurita Y., Masuda H., Terada H., Suzuki K., and Fujita K. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology 51 (1998) 595